This means doctors, patients, and pharmacists can report side effects or health problems possibly related to the drug
No, la semaglutida es un agonista sinttico del receptor de GLP-1 diseado para imitar la hormona natural GLP-1, pero con modificaciones estructurales que prolongan su vida media de 2 minutos a aproximadamente 7 das, permitiendo administracin semanal
Should be open communication
Divergent evidence requires deeper investigation to resolve contradictions
The SELECT trial showed that these benefits extend to patients with obesity or overweight conditions, even without diabetes [11]
For adults over 50, these side effects carry a slightly higher risk of dehydration and electrolyte imbalance than they do in younger patients, particularly if kidney function has begun to decline with age